Top Markets
#1 QuantixAI QuantixAI +102.94%
#2 龙虾 (Lobster) 龙虾 (Lobster) +29.51%
#3 MetaDAO MetaDAO +29.20%
#4 Rain Rain +24.16%
#5 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +19.73%
#6 Bedrock Bedrock +19.11%
#7 Pons Pons +17.61%
#8 Prom Prom +16.34%
#9 Humanity Humanity +14.45%
#10 Ontology Gas Ontology Gas +14.45%
Coin of the day
QuantixAI QuantixAI
Settings
Language
ENGLISH
Currency
USD
Theme
Metsera, Inc. Metsera, Inc.

Metsera, Inc.

MTSR
Rank in Stocks #2738
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Share Price
$70.50
Last synced: 2025-11-14
Market Cap
$7.33B
Change (1 day)
0.00%
Change (1 year)
116.32%
Country
US
Trade Metsera, Inc. (MTSR)

Category

Healthcare
P/E ratio for Metsera, Inc. (MTSR)
P/E ratio as of 2026 TTM: 0
According to Metsera, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Metsera, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.